-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
TVB-2640 is a FASN inhibitor that is expected to become a "first-in-class" and oral FASN inhibitor.
According to the press release, in the recent randomized, placebo-controlled, phase 2 trial FASCINATE-1, TVB-2640 was proved to be important in NASH in terms of steatosis, inflammation/lipotoxicity, fibrosis, metabolic biomarkers, etc.
It is worth mentioning that just early this month, Gally's wholly-owned subsidiary Gan Lai Pharmaceutical and Sagimet Biosciences jointly announced that TVB-2640 has achieved good top-line data in the Chinese cohort of randomized, placebo-controlled Phase 2 clinical trials.